A Dutch court ordered Merck to stop manufacturing and selling its subcutaneous formulation of Keytruda in eight European countries, ruling that Merck infringed a Halozyme patent. The decision highlights how formulation-level IP disputes can reshape product access across markets even when therapies remain widely used.